Project Overview

About the AMP®-CMD consortium

The Accelerating Medicines Partnership® in Common Metabolic Diseases (AMP-CMD) is a collaboration among multiple organizations including the NIDDK, FNIH, Amgen, Eli Lilly and Company, Novo Nordisk, Pfizer Inc., and researchers at academic and non-profit institutions.

The Common Metabolic Diseases Genome Atlas (CMDGA) resource is a component of AMP®-CMD being developed at the University of California San Diego as part of a larger consortium of academic, industry and non-profit institutions worldwide.  The resource is based on software developed by the ENCODE DCC at Stanford University.

Related Projects

Common Metabolic Diseases Knowledge Portal

Type 2 Diabetes Knowledge Portal

ENCODE project


This project is funded by the NIDDK under award DK105554.